<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR>               <BR>               <BR>                  <BR>                     <BR>                        Observed local adverse reactions in patients treated with ZIANA Gel were skin erythema, scaling, itching, burning, and stinging. Other most commonly reported adverse events (≥ 1% in patients treated with ZIANA Gel) were nasopharyngitis, pharyngolaryngeal pain, dry skin, cough, and sinusitis. (6.1)<BR>                         <BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact Medicis, The Dermatology Company at 1-800-900-6389 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1 Clinical Studies Experience<BR>                     <BR>                        Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse reactions that appear to be related to drug use for approximating rates.<BR>                        The safety data presented in Table 1 (below) reflects exposure to ZIANA Gel in 1,853 patients with acne vulgaris. Patients were 12 years and older and were treated once daily for 12 weeks. Adverse reactions that were reported in ≥ 1% of patients treated with ZIANA Gel were compared to adverse reactions in patients treated with clindamycin phosphate 1.2% in vehicle gel, tretinoin 0.025% in vehicle gel, and the vehicle gel alone:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="90%"><BR>                           <caption>Table 1: Adverse Reactions Reported in at Least 1% of Patients Treated with ZIANA Gel: 12-Week Studies</caption><BR>                           <col width="28%" align="left" valign="bottom"/><BR>                           <col width="18%" align="center" valign="bottom"/><BR>                           <col width="18%" align="center" valign="bottom"/><BR>                           <col width="18%" align="center" valign="bottom"/><BR>                           <col width="18%" align="center" valign="bottom"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule">ZIANA Gel<br/>N=1853<br/>N (%)</th><BR>                                 <th styleCode="Lrule">Clindamycin<br/>N=1428<br/>N (%)</th><BR>                                 <th styleCode="Lrule">Tretinoin<br/>N=846<br/>N (%)</th><BR>                                 <th styleCode="Lrule Rrule">Vehicle<br/>N=423<br/>N (%)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">PATIENTS WITH AT LEAST ONE AR</td><BR>                                 <td styleCode="Lrule">497 (27)</td><BR>                                 <td styleCode="Lrule">342 (24)</td><BR>                                 <td styleCode="Lrule">225 (27)</td><BR>                                 <td styleCode="Lrule Rrule">91 (22)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Nasopharyngitis</td><BR>                                 <td styleCode="Lrule">65 (4)</td><BR>                                 <td styleCode="Lrule">64 (5)</td><BR>                                 <td styleCode="Lrule">16 (2)</td><BR>                                 <td styleCode="Lrule Rrule">5 (1)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Pharyngolaryngeal pain</td><BR>                                 <td styleCode="Lrule">29 (2)</td><BR>                                 <td styleCode="Lrule">18 (1)</td><BR>                                 <td styleCode="Lrule">5 (1)</td><BR>                                 <td styleCode="Lrule Rrule">7 (2)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Dry skin</td><BR>                                 <td styleCode="Lrule">23 (1)</td><BR>                                 <td styleCode="Lrule">7 (1)</td><BR>                                 <td styleCode="Lrule">3 (&lt;1)</td><BR>                                 <td styleCode="Lrule Rrule">0 (0)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Cough</td><BR>                                 <td styleCode="Lrule">19 (1)</td><BR>                                 <td styleCode="Lrule">21 (2)</td><BR>                                 <td styleCode="Lrule">9 (1)</td><BR>                                 <td styleCode="Lrule Rrule">2 (1)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Sinusitis</td><BR>                                 <td styleCode="Lrule">19 (1)</td><BR>                                 <td styleCode="Lrule">19 (1)</td><BR>                                 <td styleCode="Lrule">15 (2)</td><BR>                                 <td styleCode="Lrule Rrule">4 (1)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td colspan="5" align="center" styleCode="Lrule Rrule">Note: Formulations used in all treatment arms were in the ZIANA vehicle gel.</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Cutaneous safety and tolerance evaluations were conducted at each study visit in all of the clinical trials by assessment of erythema, scaling, itching, burning, and stinging:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%"><BR>                           <caption>Table 2: ZIANA Gel-Treated Patients with Local Skin Reactions</caption><BR>                           <col width="34%" align="left" valign="top"/><BR>                           <col width="33%" align="center" valign="top"/><BR>                           <col width="33%" align="center" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule" align="center">Local Reaction</th><BR>                                 <th styleCode="Lrule">Baseline<br/>N=1835<br/>N (%)</th><BR>                                 <th styleCode="Lrule Rrule">End of Treatment<br/>N=1614<br/>N (%)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Erythema</td><BR>                                 <td styleCode="Lrule">636 (35)</td><BR>                                 <td styleCode="Lrule Rrule">416 (26)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Scaling</td><BR>                                 <td styleCode="Lrule">237 (13)</td><BR>                                 <td styleCode="Lrule Rrule">280 (17)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Itching</td><BR>                                 <td styleCode="Lrule">189 (10)</td><BR>                                 <td styleCode="Lrule Rrule">70 (4)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule">Burning</td><BR>                                 <td styleCode="Lrule">38 (2)</td><BR>                                 <td styleCode="Lrule Rrule">56 (4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Stinging</td><BR>                                 <td styleCode="Lrule">33 (2)</td><BR>                                 <td styleCode="Lrule Rrule">27 (2)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>At each study visit, application site reactions on a scale of 0 (none), 1 (mild), 2 (moderate), and 3 (severe), and the mean scores were calculated for each of the local skin reactions. In Studies 1 and 2, 1277 subjects enrolled with moderate to severe acne, 854 subjects treated with ZIANA Gel and 423 treated with vehicle. Analysis over the twelve week period demonstrated that cutaneous irritation scores for erythema, scaling, itching, burning, and stinging peaked at two weeks of therapy, and were slightly higher for the ZIANA-treated group, decreasing thereafter.<BR>                        One open-label 12-month safety study for ZIANA Gel showed a similar adverse reaction profile as seen in the 12-week studies. Eighteen out of 442 subjects (4%) reported gastrointestinal symptoms.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>